Opus Genetics to Present OPGx-BEST1 Phase 1b/2a Data and OPGx-RHO Safety Findings
Opus Genetics will present Phase 1b/2a preliminary results from its OPGx-BEST1 gene therapy and safety findings on OPGx-RHO at four May 2026 ophthalmology conferences in Denver, Boston and Fort Lauderdale. Its pipeline comprises seven AAV-based IRD therapies, led by OPGx-LCA5 and OPGx-BEST1 programs targeting LCA5 and BEST1 mutations.
1. Conference Participation Schedule
Opus Genetics leadership will attend four major ophthalmology and gene therapy meetings in May 2026. Events include the Retinal Therapeutics Innovation Summit on May 1 in Denver; ARVO Annual Meeting from May 3–7 in Denver; ASGCT Annual Meeting from May 11–15 in Boston; and Retina World Congress from May 14–17 in Fort Lauderdale.
2. OPGx-BEST1 and OPGx-RHO Data Presentations
At ARVO, the company will present previously disclosed preliminary Phase 1b/2a data from its adult OPGx-BEST1 study, showcasing cone-mediated vision restoration and new translational assay developments. At the Retinal Therapeutics Innovation Summit and ASGCT meeting, Opus will share safety and efficacy results for its OPGx-RHO silence-and-replace gene therapy in large animal efficacy and nonclinical toxicity studies.
3. Pipeline and Development Programs
Opus Genetics’ pipeline includes seven AAV-based programs targeting inherited retinal diseases, led by OPGx-LCA5 for LCA5 mutations and OPGx-BEST1 for BEST1-related degeneration, with additional candidates for RHO, CNGB1, RDH12, NMNAT1 and MERTK. The company is also advancing Phentolamine Ophthalmic Solution 0.75% through a supplemental NDA for presbyopia and a Phase 3 pivotal trial addressing post-keratorefractive dim light disturbances.